TIMP-GLIA

DRUG2 trials

Sponsors

Takeda

Conditions

Celiac Disease

Phase 1

Study of the Safety, Tolerability and Pharmacokinetics of TIMP-GLIA in Subjects With Celiac Disease

CompletedNCT03486990

TakedaCeliac Disease

Start: 2018-01-23End: 2019-07-22Updated: 2020-06-05

Phase 2

Study of the Safety, Pharmacodynamics, Efficacy, and PK of TIMP-GLIA in Subjects With Celiac Disease

CompletedNCT03738475

TakedaCeliac Disease

Start: 2018-11-11End: 2019-07-22Updated: 2020-08-12

Related Papers

TAK-101 Nanoparticles Induce Gluten-Specific Tolerance in Celiac Disease: A Randomized, Double-Blind, Placebo-Controlled Study.

2021-03-17127 citations